VASRD 7719 · Hemic and Lymphatic Systems
Chronic Myelogenous Leukemia (CML) at 30% VA Disability Rating
Data last updated September 23, 2026
In apparent remission, but still on continuous tyrosine kinase inhibitor therapy.
30% combined rating: single veteran, no dependents
$552.47
$6,629.64/year · tax-free · effective December 1, 2025
VA pays on the combined rating, not per condition: this is the amount when 30% is the veteran's combined rating, after all separate ratings are combined under 38 CFR 4.25.
The full 30% pay chart, with dependentsCombine this rating with others
VA Rating Criteria for 30%
In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors
30% Pay by Household (2026)
Monthly compensation at a 30% combined rating. Dependent additions apply at 30% and above.
| Single (no dependents) | $552.47 |
| With spouse | $617.47 |
| With spouse + 1 child | $666.47 |
| With spouse + 2 children | $698.47 |
| Single + 1 child (no spouse) | $596.47 |
Higher tier
60% Chronic Myelogenous Leukemia (CML)
$1,435.02 /mo single
Common questions about 30% for Chronic Myelogenous Leukemia (CML)
How much does a 30% VA rating for Chronic Myelogenous Leukemia (CML) pay?
VA pays on the combined rating, not per condition: this is the amount when 30% is the veteran's combined rating, after all separate ratings are combined under 38 CFR 4.25. At a 30% combined rating, a single veteran receives $552.47 per month ($6,629.64/year) under the 2026 VA rates, effective December 1, 2025. VA disability compensation is tax-free. With a spouse and one child, the monthly amount is $666.47.
What does it take to get a 30% rating for Chronic Myelogenous Leukemia (CML)?
In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors.
What's the difference between 30% and 60% for Chronic Myelogenous Leukemia (CML)?
30%: In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors. 60%: Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission.
Official sources
- 38 CFR § 4.117, Schedule of ratings, hemic and lymphatic systems (Diagnostic Code 7719)
- VA.gov, 2026 veteran disability compensation rates, effective December 1, 2025
Pay amounts on this page were last checked against VA.gov on September 22, 2026.
How these figures are checked: our methodology and the open dataset.
See all rating tiers and evidence guidance
Full VASRD criteria, best evidence, exam pitfalls, and secondary conditions for Chronic Myelogenous Leukemia (CML) are on the main condition page.
View full Chronic Myelogenous Leukemia (CML) guideVA Calc: Disability Pay
Combine your ratings & see monthly pay on your iPhone · Works offline